These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 20538483)

  • 1. Carotid duplex ultrasonography can predict outcome of intravenous alteplase therapy for hyperacute stroke.
    Koga M; Toyoda K; Nakashima T; Hyun BH; Uehara T; Yokota C; Nagatsuka K; Naritomi H; Minematsu K
    J Stroke Cerebrovasc Dis; 2011; 20(1):24-29. PubMed ID: 20538483
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Arterial occlusion sites on magnetic resonance angiography influence the efficacy of intravenous low-dose (0.6 mg/kg) alteplase therapy for ischaemic stroke.
    Nakashima T; Toyoda K; Koga M; Matsuoka H; Nagatsuka K; Takada T; Naritomi H; Minematsu K
    Int J Stroke; 2009 Dec; 4(6):425-31. PubMed ID: 19930051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and Efficacy of Intravenous Low-Dose Alteplase in Relative Contraindication Patients with Acute Ischemic Stroke.
    Ohta T; Okada K; Fukuda M; Masahira N; Matsuoka T; Tsuno T; Takemura M
    J Stroke Cerebrovasc Dis; 2018 Jul; 27(7):1844-1851. PubMed ID: 29555402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tissue plasminogen activator thrombolytic therapy for acute ischemic stroke in 4 hospital groups in Japan.
    Kono S; Deguchi K; Morimoto N; Kurata T; Deguchi S; Yamashita T; Ikeda Y; Matsuura T; Narai H; Omori N; Manabe Y; Yunoki T; Takao Y; Kawata S; Kashihara K; Abe K
    J Stroke Cerebrovasc Dis; 2013 Apr; 22(3):190-6. PubMed ID: 21968092
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study.
    Albers GW; Bates VE; Clark WM; Bell R; Verro P; Hamilton SA
    JAMA; 2000 Mar; 283(9):1145-50. PubMed ID: 10703776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical deterioration after intravenous recombinant tissue plasminogen activator treatment: a multicenter transcranial Doppler study.
    Saqqur M; Molina CA; Salam A; Siddiqui M; Ribo M; Uchino K; Calleja S; Garami Z; Khan K; Akhtar N; O'Rourke F; Shuaib A; Demchuk AM; Alexandrov AV;
    Stroke; 2007 Jan; 38(1):69-74. PubMed ID: 17138949
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multicenter Study of Intravenous Recombinant Tissue Plasminogen Activator Infusion around Hiroshima, Japan: The Hiroshima Acute Stroke Retrospective and Prospective Registry Study.
    Aoki S; Hosomi N; Sueda Y; Kono T; Takamatsu K; Ohyama H; Torii T; Kitamura T; Nomura E; Noda K; Ohtsuki T; Matsumoto M;
    J Stroke Cerebrovasc Dis; 2015 Dec; 24(12):2747-53. PubMed ID: 26360972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of early arterial reocclusion after tissue plasminogen activator-induced recanalization in acute ischemic stroke.
    Rubiera M; Alvarez-Sabín J; Ribo M; Montaner J; Santamarina E; Arenillas JF; Huertas R; Delgado P; Purroy F; Molina CA
    Stroke; 2005 Jul; 36(7):1452-6. PubMed ID: 15947260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renal impairment reduces the efficacy of thrombolytic therapy in acute ischemic stroke.
    Power A; Epstein D; Cohen D; Bathula R; Devine J; Kar A; Taube D; Duncan N; Ames D
    Cerebrovasc Dis; 2013; 35(1):45-52. PubMed ID: 23428996
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravenous alteplase at 0.6 mg/kg for acute stroke patients with basilar artery occlusion: the stroke acute management with urgent risk factor assessment and improvement (SAMURAI) Recombinant tissue plasminogen activator registry.
    Miyagi T; Koga M; Shiokawa Y; Nakagawara J; Hasegawa Y; Furui E; Kimura K; Kario K; Okuda S; Yamagami H; Okada Y; Nezu T; Maeda K; Endo K; Minematsu K; Toyoda K
    J Stroke Cerebrovasc Dis; 2013 Oct; 22(7):1098-106. PubMed ID: 23063059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early neurological deterioration within 24 hours after intravenous rt-PA therapy for stroke patients: the Stroke Acute Management with Urgent Risk Factor Assessment and Improvement rt-PA Registry.
    Mori M; Naganuma M; Okada Y; Hasegawa Y; Shiokawa Y; Nakagawara J; Furui E; Kimura K; Yamagami H; Kario K; Okuda S; Koga M; Minematsu K; Toyoda K
    Cerebrovasc Dis; 2012; 34(2):140-6. PubMed ID: 22854333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SYNTHESIS expansion: design of a nonprofit, pragmatic, randomized, controlled trial on the best fast-track endovascular treatment vs. standard intravenous alteplase for acute ischemic stroke.
    Ciccone A; Valvassori L; Nichelatti M;
    Int J Stroke; 2011 Jun; 6(3):259-65. PubMed ID: 21557814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low Alberta stroke program early computed tomography score within 3 hours of onset predicts subsequent symptomatic intracranial hemorrhage in patients treated with 0.6 mg/kg Alteplase.
    Hirano T; Sasaki M; Tomura N; Ito Y; Kobayashi S;
    J Stroke Cerebrovasc Dis; 2012 Nov; 21(8):898-902. PubMed ID: 21737309
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The correlation between admission blood glucose and intravenous rt-PA-induced arterial recanalization in acute ischemic stroke: a multi-centre TCD study.
    Saqqur M; Shuaib A; Alexandrov AV; Sebastian J; Khan K; Uchino K
    Int J Stroke; 2015 Oct; 10(7):1087-92. PubMed ID: 26332252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute carotid artery stenting in symptomatic high-grade cervical carotid artery stenosis.
    Adachi K; Sadato A; Hayakawa M; Maeda S; Hirose Y
    Neurosurg Rev; 2017 Jan; 40(1):45-51. PubMed ID: 27118378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stroke treatment with alteplase given 3.0-4.5 h after onset of acute ischaemic stroke (ECASS III): additional outcomes and subgroup analysis of a randomised controlled trial.
    Bluhmki E; Chamorro A; Dávalos A; Machnig T; Sauce C; Wahlgren N; Wardlaw J; Hacke W
    Lancet Neurol; 2009 Dec; 8(12):1095-102. PubMed ID: 19850525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thrombolysis with alteplase for acute ischemic stroke: review of SITS-MOST and other Phase IV studies.
    Külkens S; Hacke W
    Expert Rev Neurother; 2007 Jul; 7(7):783-8. PubMed ID: 17610385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of Clinical, Imaging, and Thrombus Characteristics With Recanalization of Visible Intracranial Occlusion in Patients With Acute Ischemic Stroke.
    Menon BK; Al-Ajlan FS; Najm M; Puig J; Castellanos M; Dowlatshahi D; Calleja A; Sohn SI; Ahn SH; Poppe A; Mikulik R; Asdaghi N; Field TS; Jin A; Asil T; Boulanger JM; Smith EE; Coutts SB; Barber PA; Bal S; Subramanian S; Mishra S; Trivedi A; Dey S; Eesa M; Sajobi T; Goyal M; Hill MD; Demchuk AM;
    JAMA; 2018 Sep; 320(10):1017-1026. PubMed ID: 30208455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravenous thrombolysis in young stroke patients: results from the SITS-ISTR.
    Toni D; Ahmed N; Anzini A; Lorenzano S; Brozman M; Kaste M; Mikulik R; Putaala J; Wahlgren N;
    Neurology; 2012 Mar; 78(12):880-7. PubMed ID: 22402853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lack of clinical significance of early ischemic changes on computed tomography in acute stroke.
    Patel SC; Levine SR; Tilley BC; Grotta JC; Lu M; Frankel M; Haley EC; Brott TG; Broderick JP; Horowitz S; Lyden PD; Lewandowski CA; Marler JR; Welch KM;
    JAMA; 2001 Dec; 286(22):2830-8. PubMed ID: 11735758
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.